Business Wire

Bacardi Acquires ILEGAL Mezcal – a Leading Artisanal Mezcal Brand in the U.S.

11.9.2023 15:30:00 EEST | Business Wire | Press release

Share

Bacardi Limited, the largest privately held international spirits company in the world, announced today the completion of a transaction that makes the family-owned company the sole owner of ILEGAL Mezcal®, a leading super premium artisanal mezcal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230911109816/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bacardi Acquires ILEGAL Mezcal, a Leading Artisanal Mezcal Brand in the U.S. (Photo: Business Wire)

The transaction follows a successful relationship in which Bacardi partnered with ILEGAL since 2015.

The super premium plus mezcal category is growing at a fast pace and is expected to grow at a CAGR of 16% over the next five years according to IWSR. Between now and 2027, the agave category – which includes both mezcal and tequila – is expected to be the sixth largest category globally, and it recently overtook American Whiskey to become the second largest category (by value) in the U.S. At 86% of global market share, the United States dominates the super premium mezcal category. (Source: 2022 IWSR).

“We believe that ILEGAL has the credentials to own and lead the super premium mezcal category at a global level. ILEGAL perfectly complements our portfolio and bringing it into our business sets the brand up for even greater growth as mezcal captivates more and more consumers,” says Barry Kabalkin, Vice Chairman of Bacardi Limited.

“Bacardi and ILEGAL have a shared commitment to communities, quality, and environmental sustainability that we will build upon together as we look to invest for the long term. As a family-owned business for seven generations, we are always building for the future to maintain the legacy that is Bacardi,” says Mahesh Madhavan, Bacardi Limited Chief Executive Officer.

ILEGAL, recognized globally for its lifestyle branding, also prides itself on being a responsible and sustainable business. They work with fourth-generation maestros mezcaleros in Santiago Matatlán, Oaxaca, Mexico. ILEGAL Mezcal is double distilled in small batches using 100% Espadin agave. ILEGAL Mezcal is 100% natural and uses no artificial colors, yeasts, flavors, or additives. It is certified as artisanal mezcal by the Consejo Regulador del Mezcal (CRM).

John Rexer created ILEGAL in 2006, after years of working with small distillers in Oaxaca to make mezcal for his bar in Guatemala. John’s goal has been to bring the finest artisanal mezcal to a global market. He has worked closely with the distillers in Oaxaca to create sustainable jobs, and to be a positive force in protecting the environment and preserving local culture. John will continue to guide the vision of the brand.

“We are excited about the next stage of the journey,” says John Rexer. “Success for ILEGAL goes beyond seeing more of our bottles on shelves; it’s about building our business the right way. We will always be committed to artisanal production, the Oaxacan community, and our core values. Being a part of Bacardi will bring ILEGAL to a larger audience while maintaining our commitment to sustainability and growing the business responsibly.”

ILEGAL Mezcal is available in Joven, a full-bodied agave flavor with a light smoke; Reposado, aged six months in medium-charred American oak; and Añejo, aged to taste for 13 months using a combination of new and used American oak, medium char barrels.

Terms of the transaction were not disclosed.

About Bacardi Limited

Bacardi Limited, the largest privately held international spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 161 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 9,000, operates production facilities in 10 countries, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on LinkedIn or Instagram.

About ILEGAL Mezcal

ILEGAL Mezcal was founded in 2006 and is today one of the leading artisanal mezcals in the world. ILEGAL Mezcal is sold in over 40 countries and has won numerous awards for both quality and branding. The brand has won countless awards including a Gold Honor Shorty Award for Brand Identity and was named Agave Spirit of 2022 by Bloomberg. The company prides itself on bringing to market fine aged mezcals as well as its joven expressions. ILEGAL is produced and bottled in Oaxaca, Mexico. The production is 100% artisanal, using ripe espadin agave, pit ovens, tahona mills, and small copper stills. Visit www.ilegalmezcal.com or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jessica Merz, VP Global Corporate Communications, jmerz@bacardi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a

Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release

Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye